CONTENTS

How to use this book i

Preface iii

1 Thalidomide 1

1.1 Introduction 1
1.2 Animal data 1
1.3 Human morbidity and mortality 2
1.4 Specific congenital malformations 3
1.5 Other birth defects 5
1.6 Thalidomide-resistant pregnancies 5
1.7 Differential diagnosis of the thalidomide syndrome 5
1.8 Experimental aspects of the thalidomide embryopathy 6
1.9 Summary and conclusions 6

2 Amphetamines 9

2.1 Introduction 9
2.2 Animal data 9
2.3 Clinical studies 10
2.4 Conclusions 12

3 Tricyclic Antidepressants 15

3.1 Introduction 15
3.2 Animal data 15
3.3 Human studies 15
3.4 Human case reports not included 16
3.5 Negative studies 17
3.6 Recommendations for use of antidepressants in pregnancy 17
3.7 Summary 17

4 Lithium 19

4.1 Introduction 19
4.2 Animal data 19
4.3 Human studies 20
5 Ethanol

5.1 Introduction
5.2 The fetal alcohol syndrome
5.3 Animal studies
5.4 Human congenital malformations
5.5 Complications of pregnancy and labour
5.6 Negative study
5.7 Combined syndromes
5.8 Disulfiram
  5.8.1 Animal data
  5.8.2 Congenital malformations
5.9 Summary and conclusions

6 Cigarette Smoking

6.1 Introduction
6.2 Adverse effects on the fetus
6.3 Placental effects
6.4 Passive maternal smoking
6.5 Smoking in conjunction with other substances of abuse
6.6 Pathogenesis
6.7 Summary

7 Caffeine

7.1 Introduction
7.2 Animal data
7.3 Negative human studies
7.4 Case reports
7.5 Pharmacokinetics in the maternal–fetal unit
7.6 Reports not included
7.7 Summary

8 Drugs of Abuse

8.1 Introduction
8.2 Cannabis (marijuana)
  8.2.1 Introduction
  8.2.2 Animal data
  8.2.3 Dysmorphogenesis in humans
  8.2.4 Prenatal complications
  8.2.5 Cancer risk
8.3 Cocaine
  8.3.1 Animal data
  8.3.2 Dysmorphogenesis in humans
  8.3.3 Auditory defects
13.8 Treatment of rheumatic diseases in pregnancy 125
13.9 Summary and conclusions 125

14 Anaesthetic Agents [General and Local Anaesthetics] 131

14.1 Introduction 131
14.2 Suxamethonium and congeners 131
  14.2.1 Experimental data 131
  14.2.2 Negative clinical data 131
  14.2.3 Interaction of succinylcholine with hypermagnesaemia 132
14.3 Propofol 132
14.4 Surgical atmospheric pollution 132
14.5 Fetal hazards of general and local anaesthesia 132
14.6 Local anaesthetics 133
  14.6.1 Introduction 133
  14.6.2 Experimental data 133
14.7 Adverse effects of local anaesthetics in the newborn infant 134
14.8 Maternal complications 135
14.9 Negative reports 136
14.10 Conclusions 137

15 Sympathomimetic Agents 141

15.1 Introduction 141
15.2 Animal data 141
15.3 Congenital malformations 142
15.4 Fetal complications 143
15.5 Maternal complications during pregnancy 143
15.6 Pregnancy complications of anti-asthma therapy 146
15.7 Metabolic disturbances in the maternal–fetal unit 147
15.8 Neonatal complications 148
15.9 Interaction with prostaglandin synthetase inhibitors 148
15.10 Negative reports 149
15.11 Articles considered but not included 149
15.12 Comment 149

16 Antihypertensive Drugs, and β-Adrenergic Receptor Blocking Agents 153

16.1 Introduction 153
16.2 α-Methyldopa 153
  16.2.1 Perinatal outcome 153
  16.2.2 Long-term follow-up 155
  16.2.3 Growth and development 155
16.3 Angiotensin-converting enzyme (ACE) inhibitors 156
  16.3.1 Introduction 156
  16.3.2 Pregnancy outcome 156
  16.3.3 Oligohydramnios and neonatal anuria 156
  16.3.4 Conclusion 158
16.4 β-Adrenergic receptor blocking agents 158
  16.4.1 Introduction 158
  16.4.2 Theoretical considerations 158
  16.4.3 Outcome of pregnancy 159
  16.4.4 Intrauterine growth retardation 160
16.4.5 Perinatal complications 160
16.4.6 Metabolic effects 161
16.4.7 Allergy 161
16.4.8 Fetal and uteroplacental haemodynamics 161
16.4.9 Negative reports 162
16.4.10 The merits of β-adrenergic receptor blocking agents in hypertension of pregnancy 162
16.5 Comment 163
16.6 Hydralazine 163
16.7 Minoxidil 164
16.8 Clonidine and lofexidine 164
16.9 Reserpine 165
16.10 Summary and conclusions 165

17 Diuretics 169

17.1 Introduction 169
17.2 Effects of diuretics in pregnancy 169
17.3 Furosemide 170
17.4 Thiazide diuretics 170
17.5 Triamterene 170
17.6 Negative report 170
17.7 Animal data 171

18 Penicillamine and Gold 173

18.1 Introduction 173
18.2 Gold 173
18.2.1 Animal data 173
18.2.2 Pharmacokinetics 173
18.2.3 Negative studies 173
18.2.4 Congenital malformations 174
18.3 Penicillamine 174
18.3.1 Congenital malformations 174
18.3.2 Negative studies 175
18.4 Comment and conclusions 176

19 Antibiotics and Chemotherapeutic Agents 179

19.1 Introduction 179
19.2 Antibiotics and stillbirth 179
19.3 Aminoglycosides 179
19.3.1 Introduction 179
19.3.2 Experimental data 180
19.3.3 Human vestibular apparatus 180
19.3.4 Pharmacokinetics 180
19.3.5 Comment 181
19.4 Ampicillin 181
19.4.1 Pharmacokinetics 181
19.4.2 Animal data 181
19.4.3 Acute anaphylaxis in the mother 182
19.4.4 Negative human study 182
19.5 Cephalosporins 182
19.5.1 Human studies 182
21.3 Mefloquine 207
21.4 Mepacrine 207
21.5 Proguanil 207
21.6 Pyrimethamine 207
  21.6.1 Pyrimethamine with dapsone 208
  21.6.2 Pyrimethamine with sulphadoxine (Fansidar) 208
21.7 Quinine 208
  21.7.1 Fetal toxicity 208
  21.7.2 Quinine action on pancreatic β-cells 209
21.8 Information not available 209
21.9 Conclusions and clinical recommendations 210

22 Vaccines 211

22.1 Introduction 211
22.2 Bacille Calmette–Guerin (BCG) vaccine 211
22.3 Influenza virus vaccine 211
  22.3.1 Neurotoxicity 212
  22.3.2 Negative human studies 212
22.4 Measles vaccine (including measles-mumps-rubella MNR vaccine) 213
22.5 Mumps vaccine 213
22.6 Poliomyelitis vaccine 213
  22.6.1 Human studies 213
22.7 Rabies vaccine 214
22.8 Rubella vaccine 214
  22.8.1 World Health Organization findings and recommendations 214
  22.8.2 Use in pregnancy – negative studies 215
  22.8.3 Recommendations for rubella immunisation 216
22.9 Smallpox vaccine 216
22.10 TC-83 Venezuelan equine encephalitis vaccine 217
22.11 Yellow fever vaccine 217
22.12 Conclusions and recommendations 217

23 Anticoagulants 221

23.1 Introduction 221
23.2 Heparin 221
  23.2.1 Osteopenia in the mother 221
  23.2.2 Haemorrhagic complications 222
  23.2.3 Outcome of pregnancy 222
  23.2.4 Toxic epidermal necrolysis 223
  23.2.5 A contrary view 223
  23.2.6 Summary 223
23.3 Warfarin sodium 224
  23.3.1 Introduction 224
  23.3.2 Fetal warfarin syndrome and warfarin embryopathy 224
  23.3.3 Fetal mortality 225
  23.3.4 Isolated case reports 226
  23.3.5 Differential diagnosis of the fetal warfarin syndrome 226
  23.3.6 Pathogenesis of warfarin embryopathy 227
  23.3.7 Other publications considered 227
  23.3.8 Summary 228
23.4 General effects of anticoagulation in pregnancy 228
23.5 Therapeutic considerations
23.5.1 Antithrombin III congenital defect 229
23.5.2 Congenital factor XIII deficiency 229
23.5.3 Valve prosthesis in pregnancy 230
23.5.4 Thromboembolic disease 230

24 Haematinics
24.1 Introduction 233
24.2 Animal data 233
24.3 Negative human data 233
24.4 Conclusion 234

25 Drugs Acting on the Gastrointestinal Tract
25.1 Introduction 235
25.2 Bismuth 235
25.3 Carbenoxolone 235
25.4 Cimetidine 235
25.4.1 Animal data 235
25.4.2 Human fetal hepatotoxicity 236
25.5 Ranitidine 236
25.6 Sulphasalazine 236
25.6.1 Human congenital malformations 236
25.6.2 Kernicterus 237
25.6.3 Male infertility 237
25.6.4 Negative human studies 238
25.7 Conclusions 238

26 Antiemetic Agents
26.1 Bendectin (Debendox) 241
26.1.1 Introduction 241
26.1.2 Large-scale studies of Bendectin teratogenicity 241
26.1.3 Congenital malformations 242
26.1.4 Negative human studies 242
26.2 The problem of identifying a low-grade teratogen 243
26.3 Antiemetic agents other than Bendectin 244
26.3.1 Animal data 244
26.3.2 Negative human studies 244
26.4 Atropine and other parasympatholytic agents 245
26.4.1 Pharmacokinetics 245
26.4.2 Congenital malformations 245
26.4.3 Maternal and fetal effects 246
26.5 Prochlorperazine 246
26.5.1 Congenital malformations of the limbs 246

27 Vitamins and the Retinoids
27.1 Introduction 249
27.2 Experimental data 250
27.3 Human fetal effects of vitamin A and the retinoids 252
27.4 Other articles considered 257
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>27.5</td>
<td>Differential diagnosis of retinoid embryopathy</td>
<td>258</td>
</tr>
<tr>
<td>27.6</td>
<td>Mechanisms of retinoid teratogenicity</td>
<td>258</td>
</tr>
<tr>
<td>27.7</td>
<td>Principles of behavioural teratology reflected by the retinoids</td>
<td>259</td>
</tr>
<tr>
<td>27.8</td>
<td>Topical retinoic acids</td>
<td>259</td>
</tr>
<tr>
<td>27.9</td>
<td>Recommendations for the use of vitamin A during pregnancy</td>
<td>259</td>
</tr>
<tr>
<td>27.10</td>
<td>Vitamin D</td>
<td>260</td>
</tr>
<tr>
<td>27.10.1</td>
<td>Introduction</td>
<td>260</td>
</tr>
<tr>
<td>27.10.2</td>
<td>Animal data</td>
<td>260</td>
</tr>
<tr>
<td>27.10.3</td>
<td>Negative human study</td>
<td>260</td>
</tr>
<tr>
<td>28</td>
<td>Corticosteroids</td>
<td>265</td>
</tr>
<tr>
<td>28.1</td>
<td>Introduction</td>
<td>265</td>
</tr>
<tr>
<td>28.2</td>
<td>Animal data</td>
<td>256</td>
</tr>
<tr>
<td>28.3</td>
<td>Negative human studies - congenital malformations</td>
<td>266</td>
</tr>
<tr>
<td>28.4</td>
<td>Effects on pregnancy and labour</td>
<td>266</td>
</tr>
<tr>
<td>28.5</td>
<td>Neonatal status</td>
<td>267</td>
</tr>
<tr>
<td>28.6</td>
<td>Head circumference and brain maturation</td>
<td>268</td>
</tr>
<tr>
<td>28.7</td>
<td>Dexamethasone</td>
<td>269</td>
</tr>
<tr>
<td>28.8</td>
<td>Conclusions</td>
<td>269</td>
</tr>
<tr>
<td>29</td>
<td>Hormonal Contraceptives</td>
<td>273</td>
</tr>
<tr>
<td>29.1</td>
<td>Introduction</td>
<td>273</td>
</tr>
<tr>
<td>29.2</td>
<td>Congenital malformations</td>
<td>273</td>
</tr>
<tr>
<td>29.3</td>
<td>Disturbances of fetal sex expression</td>
<td>276</td>
</tr>
<tr>
<td>29.4</td>
<td>Neoplastic change in the infant</td>
<td>277</td>
</tr>
<tr>
<td>29.5</td>
<td>Chromosomal abnormalities</td>
<td>277</td>
</tr>
<tr>
<td>29.6</td>
<td>Twin pregnancies</td>
<td>278</td>
</tr>
<tr>
<td>29.7</td>
<td>Maternal complications</td>
<td>278</td>
</tr>
<tr>
<td>29.8</td>
<td>Negative reports</td>
<td>279</td>
</tr>
<tr>
<td>29.9</td>
<td>Hormonal pregnancy tests</td>
<td>281</td>
</tr>
<tr>
<td>29.10</td>
<td>Comment and conclusions</td>
<td>281</td>
</tr>
<tr>
<td>30</td>
<td>Diethylstilboestrol and Related Agents Affecting Fetal Sex Hormone Development</td>
<td>285</td>
</tr>
<tr>
<td>30.1</td>
<td>Introduction</td>
<td>285</td>
</tr>
<tr>
<td>30.2</td>
<td>Clomiphene</td>
<td>285</td>
</tr>
<tr>
<td>30.2.1</td>
<td>Congenital malformations</td>
<td>285</td>
</tr>
<tr>
<td>30.2.2</td>
<td>Complications of pregnancy</td>
<td>286</td>
</tr>
<tr>
<td>30.2.3</td>
<td>Negative results</td>
<td>286</td>
</tr>
<tr>
<td>30.3</td>
<td>Danazol</td>
<td>286</td>
</tr>
<tr>
<td>30.3.1</td>
<td>Antigonadotrophic effects</td>
<td>287</td>
</tr>
<tr>
<td>30.3.2</td>
<td>Effects on the male fetus</td>
<td>288</td>
</tr>
<tr>
<td>30.4</td>
<td>Diethylstilboestrol</td>
<td>288</td>
</tr>
<tr>
<td>30.4.1</td>
<td>Introduction</td>
<td>288</td>
</tr>
<tr>
<td>30.4.2</td>
<td>Neoplasia of the female genital tract</td>
<td>288</td>
</tr>
<tr>
<td>30.4.3</td>
<td>Uterine and vaginal structural abnormalities</td>
<td>289</td>
</tr>
<tr>
<td>30.4.4</td>
<td>Disturbances in ovulation and fertility</td>
<td>290</td>
</tr>
<tr>
<td>30.4.5</td>
<td>Complications in pregnancy of the offspring</td>
<td>291</td>
</tr>
<tr>
<td>30.4.6</td>
<td>Hormonal and menstrual abnormalities</td>
<td>292</td>
</tr>
<tr>
<td>30.4.7</td>
<td>Abnormalities in the male offspring</td>
<td>293</td>
</tr>
<tr>
<td>30.4.8</td>
<td>Miscellaneous pathological effects</td>
<td>294</td>
</tr>
</tbody>
</table>
30.4.9 A challenge to the evidence
30.4.10 Summary
30.5 Medroxyprogesterone acetate
30.6 Progestogens
30.7 Summary

31 Spermicidal Agents

31.1 Introduction
31.2 Animal and experimental data
31.3 Human studies
31.4 Negative studies in humans
31.5 Conclusion

32 Thyroid and Antithyroid Drugs

32.1 Introduction
32.2 Radioactive iodine
32.3 Iodine-containing anti-asthmatic medicines
32.4 Iodine-containing radiocontrast media
32.5 Iodine-containing douche
32.6 β-Adrenergic receptor blocking agents
  32.6.1 Introduction
  32.6.2 Negative reports
32.7 Propylthiouracil and the thioamides
  32.7.1 Introduction
  32.7.2 Effects on the fetal thyroid gland
  32.7.3 Fetal morbidity
  32.7.4 Negative results
  32.7.5 Aplasia cutis
32.8 Combined thyroid and antithyroid therapy in pregnancy
32.9 Effects of radioactive fallout
  32.9.1 Introduction
  32.9.2 Mental deficiency
32.10 Management of hyperthyroidism in pregnancy – general principles
32.11 Summary and conclusions

33 Oral Hypoglycaemic Agents

33.1 Introduction
33.2 Biguanides
33.3 Sulphonylureas (other than tolbutamide)
  33.3.1 Fetal loss, and outcome of pregnancy
  33.3.2 Carbutamide
  33.3.3 Chlorpropamide
33.4 Tolbutamide
  33.4.1 Animal data
  33.4.2 Transplacental access to the human fetus
  33.4.3 Adverse effects on the fetus
33.5 The relevance of glucose control in pregnancy
33.6 Reports not included
33.7 Conclusion
34 Prostaglandins

34.1 Introduction
34.2 Human case reports
34.3 Negative human studies
34.4 Animal data

35 Cytotoxic and Immunosuppressive Agents

35.1 Introduction
35.2 Anthracyclines
35.3 Azathioprine
35.4 Busulphan
35.5 Chlorambucil
   35.5.1 Animal data
   35.5.2 Human reports
35.6 Cyclophosphamide (also 4-hydroxy-\(\text{cyclophosphamide}\); \(\text{dechlorocyclophosphamide}\))
   35.6.1 Animal data
   35.6.2 Human reports
   35.6.3 Mutagenesis
35.7 Cyclosporin
   35.7.1 Human experience
   35.7.2 Pharmacokinetics
35.8 Cytosine arabinoside
35.9 Methotrexate and aminopterin
   35.9.1 Introduction
   35.9.2 Animal data
   35.9.3 Human embryotoxicity
35.10 Podophyllin
   35.10.1 Negative report
35.11 Procarbazine
   35.11.1 Human case reports
35.12 Combined cytotoxic chemotherapy
35.13 Pregnancy outcome in patients undergoing immunosuppressive therapy
35.14 Acute leukemia in pregnancy
35.15 Chemotherapy of gestational trophoblastic tumours
35.16 Parenthood in male homograft recipients

APPENDIXES

Appendix I Abnormal fetal genitourinary system development associated with drugs
Appendix II Drugs associated with polydactyly and syndactyly
Appendix III Reported association of congenital abnormalities of bones and intrauterine drug exposure
Appendix IV Limb reduction deformities associated with drug exposure in utero
Appendix V Drug-related anencephaly, exencephaly and spina bifida in humans
Appendix VI Human congenital cardiac defects that have been associated with drug exposure in utero
Appendix VII Drugs associated with congenital hearing loss and/or microtia
Appendix VIII Drugs associated with congenital ocular defects
Appendix IX  Drugs associated with oral clefts  447
Appendix X  X-irradiation  461
Appendix XI  Behavioural teratology  467
Appendix XII  The kinetics of drugs during pregnancy – general principles  471
Appendix XIII  Evaluation and prediction of drug safety in pregnancy  475
Appendix XIV  Attempted suicide with drugs in pregnancy  485

Index of Drugs  491
Index of Side Effects  497